CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 375 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,400,000 | -20.9% | 96,935 | -2.1% | 0.00% | 0.0% |
| Q2 2023 | $5,560,000 | +27.8% | 99,033 | +2.9% | 0.00% | 0.0% |
| Q1 2023 | $4,352,000 | +7.5% | 96,242 | -3.4% | 0.00% | 0.0% |
| Q4 2022 | $4,048,000 | -53.9% | 99,606 | -25.9% | 0.00% | -66.7% |
| Q3 2022 | $8,780,000 | -35.9% | 134,371 | -40.4% | 0.00% | -25.0% |
| Q2 2022 | $13,705,000 | -9.8% | 225,517 | -6.8% | 0.00% | 0.0% |
| Q1 2022 | $15,189,000 | -15.9% | 241,983 | +1.5% | 0.00% | 0.0% |
| Q4 2021 | $18,061,000 | -32.7% | 238,332 | -0.6% | 0.00% | -42.9% |
| Q3 2021 | $26,846,000 | -29.7% | 239,843 | +1.6% | 0.01% | -30.0% |
| Q2 2021 | $38,201,000 | +36.6% | 235,960 | +2.8% | 0.01% | +25.0% |
| Q1 2021 | $27,975,000 | -17.7% | 229,588 | +3.4% | 0.01% | -20.0% |
| Q4 2020 | $34,007,000 | +100.6% | 222,113 | +9.6% | 0.01% | +66.7% |
| Q3 2020 | $16,952,000 | +28.9% | 202,672 | +13.3% | 0.01% | +20.0% |
| Q2 2020 | $13,151,000 | +170.4% | 178,942 | +56.1% | 0.01% | +150.0% |
| Q1 2020 | $4,863,000 | -26.2% | 114,657 | +5.9% | 0.00% | 0.0% |
| Q4 2019 | $6,593,000 | +51.7% | 108,237 | +2.1% | 0.00% | 0.0% |
| Q3 2019 | $4,346,000 | -23.4% | 106,031 | -12.0% | 0.00% | 0.0% |
| Q2 2019 | $5,672,000 | +130.9% | 120,425 | +75.1% | 0.00% | +100.0% |
| Q1 2019 | $2,456,000 | +43.8% | 68,760 | +15.0% | 0.00% | 0.0% |
| Q4 2018 | $1,708,000 | -49.8% | 59,787 | -22.1% | 0.00% | 0.0% |
| Q3 2018 | $3,404,000 | +7.5% | 76,758 | +42.4% | 0.00% | 0.0% |
| Q2 2018 | $3,167,000 | +160.2% | 53,892 | +102.4% | 0.00% | 0.0% |
| Q1 2018 | $1,217,000 | +274.5% | 26,620 | +91.9% | 0.00% | – |
| Q4 2017 | $325,000 | +132.1% | 13,869 | +76.7% | 0.00% | – |
| Q3 2017 | $140,000 | +164.2% | 7,850 | +136.1% | 0.00% | – |
| Q2 2017 | $53,000 | -28.4% | 3,325 | -1.5% | 0.00% | – |
| Q1 2017 | $74,000 | – | 3,376 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |